peplexicon
Choose your depth

Context, anatomy, and key evidence

← Peptide library

GHRH analog

CJC-1295

Published evidence · coverage incomplete

Anatomy in the research

Explore the structures studied.

These are anatomical mentions in cited research—not established treatment targets or proof of benefit in people.

General anatomy view only. No peptide-specific structures are highlighted.

Skin · 1 cited passage(s)

A compatible 3D model is not connected yet; the research is available below.

Population: female internet forum users

Choice to use CJC-1295 centered on weight loss, muscle enhancement, youthful skin, improved sleep, and injury healing.

Applies only to the source-defined population, formulation, dose, and assessment period.

Evidence relationship: supports

Read finding and source →

At a glance

What is it—and why does it matter?

CJC-1295 is described as a long-acting GHRH analog, meaning it is a modified form of GHRH designed for prolonged activity. The study narrowed initial search results to 9 sites by applying exclusion criteria requiring female use and evidence of forum activity. When administered at 48 h or 72 h intervals, CJC-1295 was associated with higher body weight and length than placebo in GHRHKO mice, yet did not fully normalize growth.

Sources for this introduction: [1] [2] [3]

This published profile is a reference in progress. Findings retain their source context; missing topics are marked below.

What is it?

A molecule, not a product name.

Identity

CJC-1295 is categorized here among synthetic GHRH analog peptides (i.e., peptides designed to mimic GHRH).

Sources[4]pubmedAnalysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry.GHRH and its synthetic analogs (sermorelin/CJC-1293, tesamorelin, and CJC-1295)
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “GHRH and its synthetic analogs (sermorelin/CJC-1293, tesamorelin, and CJC-1295)”

    Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry. · Abstract

    pubmed:41138283:4151bd4f6d92:4151bd4f6d92

Identity

CJC-1295 is categorized here as a GHRH analogue (a peptide designed to mimic GHRH).

Sources[5]pubmedA new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review.peptides-including growth hormone secretagogues (e.g., Ipamorelin), growth hormone-releasing hormone analogues (e.g., CJC-1295, Sermorelin)
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “peptides-including growth hormone secretagogues (e.g., Ipamorelin), growth hormone-releasing hormone analogues (e.g., CJC-1295, Sermorelin)”

    A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review. · Abstract

    pubmed:41880199:39c6683290a1:39c6683290a1

Identity

CJC-1295 is described as a long-acting GHRH analog, meaning it is a modified form of GHRH designed for prolonged activity.

Sources[2]pubmedProlonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.The objective of this study was to examine the pharmacokinetic profile, pharmacodynamic effects, and safety of CJC-1295, a long-acting GHRH analog.
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “The objective of this study was to examine the pharmacokinetic profile, pharmacodynamic effects, and safety of CJC-1295, a long-acting GHRH analog.”

    Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. · OBJECTIVE

    pubmed:16352683:9ca2ad6f3331:9ca2ad6f3331

Identity

The abstract categorizes CJC-1295 (with Drug Affinity Complex [DAC]) and CJC-1295 (without DAC) as growth hormone-releasing hormone (GHRH) analogue peptides.

Sources[8]pubmedThe emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.The agents most commonly encountered in clinical practice and online self-administration protocols include growth hormone-releasing hormone (GHRH) analogues (e.g., sermorelin, tesamorelin, CJC-1295 with Drug Affinity Complex [DAC], CJC-1295 without DAC)
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “The agents most commonly encountered in clinical practice and online self-administration protocols include growth hormone-releasing hormone (GHRH) analogues (e.g., sermorelin, tesamorelin, CJC-1295 with Drug Affinity Complex [DAC], CJC-1295 without DAC)”

    The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. · Abstract

    pubmed:42395176:9df538e1edba:9df538e1edba

Identity

In this review, CJC-1295 is categorized as a growth hormone axis secretagogue (a peptide class intended to stimulate the growth hormone axis).

Sources[7]pubmedInjectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications.Regenerative peptides (e.g., body protection compound-157 and thymosin derivatives) and growth hormone axis secretagogues (e.g., CJC-1295, ipamorelin, and tesamorelin) remain investigational, with uncertain safety profiles, product quality concerns, and widespread antidoping restrictions.
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Regenerative peptides (e.g., body protection compound-157 and thymosin derivatives) and growth hormone axis secretagogues (e.g., CJC-1295, ipamorelin, and tesamorelin) remain investigational, with uncertain safety profiles, product quality concerns, and widespread antidoping restrictions.”

    Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications. · RESULTS

    pubmed:42160466:862312190ba6:862312190ba6

Identity

In this source, CJC-1295 is characterized as a synthetic analogue of growth hormone.

Sources[3]pubmedNetnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions.The study used "netnography" to explore female use of CJC-1295, a synthetic growth hormone analogue from the perspectives contained in Internet forum activity.
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “The study used "netnography" to explore female use of CJC-1295, a synthetic growth hormone analogue from the perspectives contained in Internet forum activity.”

    Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. · OBJECTIVES

    pubmed:26771670:48401f747b0a:48401f747b0a

How does it work?

Target, response, and disposition.

Mechanism

The study narrowed initial search results to 9 sites by applying exclusion criteria requiring female use and evidence of forum activity.

Sources[3]pubmedNetnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions.The study used "netnography" to explore female use of CJC-1295, a synthetic growth hormone analogue from the perspectives contained in Internet forum activity.[3]pubmedNetnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions.Following application of exclusion criteria to confine to female use and evidence of forum activity, 9 sites remained.
Source records
2
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “The study used "netnography" to explore female use of CJC-1295, a synthetic growth hormone analogue from the perspectives contained in Internet forum activity.”

    Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. · OBJECTIVES

    pubmed:26771670:48401f747b0a:48401f747b0a
  2. supports · Source-backed record
    “Following application of exclusion criteria to confine to female use and evidence of forum activity, 9 sites remained.”

    Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. · METHODS

    pubmed:26771670:48401f747b0a:48401f747b0a

Mechanism

Within the set of peptides discussed for aging-related applications, CJC-1295 is grouped with agents described as modulating growth hormone.

Sources[6]pubmedTherapeutic peptides in gerontology: mechanisms and applications for healthy aging.Nine peptides were identified spanning diverse aging interventions: metabolic restoration (tirzepatide), telomere biology (epitalon), dermal regeneration (GHK-Cu), tissue repair (BPC-157, TB-500), neuroprotection (Semax), growth hormone modulation (CJC-1295, ipamorelin), and sexual function (bremelanotide).
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Nine peptides were identified spanning diverse aging interventions: metabolic restoration (tirzepatide), telomere biology (epitalon), dermal regeneration (GHK-Cu), tissue repair (BPC-157, TB-500), neuroprotection (Semax), growth hormone modulation (CJC-1295, ipamorelin), and sexual function (bremelanotide).”

    Therapeutic peptides in gerontology: mechanisms and applications for healthy aging. · RESULTS

    pubmed:42021992:2d2b245156c8:2d2b245156c8

Mechanism

The source states these unregulated peptide “research compounds” are intended to modulate the growth hormone–insulin-like growth factor-1 (GH–IGF-1) axis.

Sources[8]pubmedThe emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.Performance-enhancing drugs (PEDs) marketed as "research compounds" include unregulated peptides intended to modulate the growth hormone-insulin-like growth factor-1 (GH-IGF-1) axis.
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Performance-enhancing drugs (PEDs) marketed as "research compounds" include unregulated peptides intended to modulate the growth hormone-insulin-like growth factor-1 (GH-IGF-1) axis.”

    The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. · Abstract

    pubmed:42395176:9df538e1edba:9df538e1edba

What has been studied?

What the evidence says.

Study findings

In the forum discussions analyzed, the stated motivations for CJC-1295 use included weight loss, muscle enhancement, youthful skin, improved sleep, and injury healing (these are reported reasons, not demonstrated clinical effects).

Sources[3]pubmedNetnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions.Choice to use CJC-1295 centered on weight loss, muscle enhancement, youthful skin, improved sleep, and injury healing.
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Choice to use CJC-1295 centered on weight loss, muscle enhancement, youthful skin, improved sleep, and injury healing.”

    Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. · RESULTS

    pubmed:26771670:48401f747b0a:48401f747b0a

Study findings

The paper’s stated objective is analytical method development (nano-LC-Q/Orbitrap MS) to enable both screening and confirmatory detection of CJC-1295 in urine in a WADA-compliant workflow.

Sources[4]pubmedAnalysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry.The present study aimed to develop a robust nano-LC quadrupole/orbitrap mass spectrometry (nano-LC-Q/Orbitrap MS) method for both screening and confirmation analyses of GHRH and its synthetic analogs (sermorelin/CJC-1293, tesamorelin, and CJC-1295)
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “The present study aimed to develop a robust nano-LC quadrupole/orbitrap mass spectrometry (nano-LC-Q/Orbitrap MS) method for both screening and confirmation analyses of GHRH and its synthetic analogs (sermorelin/CJC-1293, tesamorelin, and CJC-1295)”

    Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry. · Abstract

    pubmed:41138283:4151bd4f6d92:4151bd4f6d92

Study findings

When administered at 48 h or 72 h intervals, CJC-1295 was associated with higher body weight and length than placebo in GHRHKO mice, yet did not fully normalize growth.

Sources[1]doiOnce-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouseMice treated every 48 and 72 h reached higher body weight and length than placebo-treated animals, without full growth normalization.
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Mice treated every 48 and 72 h reached higher body weight and length than placebo-treated animals, without full growth normalization.”

    Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse · Abstract

    doi:10.1152/ajpendo.00201.2006:c44aaf5ec39f:c44aaf5ec39f

Risks and interactions

Risks, organized for scanning.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Products and regulatory status

Same ingredient. Different records.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Administration context

The practical clinical context.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Research status + gaps

What still needs better answers?

  • No publishable claim yet for: administration, contraindication, interaction, regulatory, safety
  • 92 compiled claim(s) withheld by automated assurance: assurance_score_below_0.58 (41), assurance_score_below_0.72 (40), current_regulatory_source_required (19), extraction_ambiguity (71), high_risk_requires_regulatory_or_two_independent_sources (49), no_direct_support (69), proposal_not_staged (2)

These are the limits of this profile, not an exhaustive list of scientific uncertainties.

References + discovery

Open the records yourself.

  1. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse ↗

    doi · published 2006-12-01 · retrieved 2026-09-09T18:02:02Z

  2. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. ↗

    pubmed · published 2006-03-01 · retrieved 2026-09-04T19:14:30Z

  3. Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. ↗

    pubmed · published 2016-01-02 · retrieved 2026-09-09T21:34:57Z

  4. Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry. ↗

    pubmed · published 2026-01-15 · retrieved 2026-08-26T08:42:26Z

  5. A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review. ↗

    pubmed · published 2026-07-01 · retrieved 2026-08-26T08:42:26Z

  6. Therapeutic peptides in gerontology: mechanisms and applications for healthy aging. ↗

    pubmed · published 2026-01-01 · retrieved 2026-08-26T08:42:26Z

  7. Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications. ↗

    pubmed · published 2026-05-01 · retrieved 2026-08-17T23:10:15Z

  8. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. ↗

    pubmed · published 2026-01-01 · retrieved 2026-08-17T23:10:15Z

Publication history and provenance

Version 1 · Automated assessment · 2026-09-09T21:34:57Z

033d5b4e8ab267d85b1c32012d78ec61fa7e23245a492bdd28bf6f974087a4d8